Patents Issued in January 24, 2019
  • Publication number: 20190022006
    Abstract: The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 ?m sieve and to methods of making the same.
    Type: Application
    Filed: December 12, 2017
    Publication date: January 24, 2019
    Applicant: AZTherapies, Inc.
    Inventors: David R. ELMALEH, Juan B. Gonzalez
  • Publication number: 20190022007
    Abstract: A mesosilicalite nanocarrier having a hierarchical silicalite characterized by a molar ratio of aluminum to silica in a range of 1:3000 to 1:1000. The hierarchical silicalite includes mesopores of a hexagonal structure, and micropores of silicalite structure with a microporous volume in the range of 0.05 cc/g to 0.1 cc/g. The nanocarrier has a mesophase content in the range of 30 wt % to 70 wt %, a microphase content in the range of 30 wt % to 70 wt %, and a mean pore diameter in the range of 1.5 nm to 5.5 nm. A method of preparing the stable mesosilicalite nanocarrier with hierarchical micro/mesopores to load an antioxidant or drug for targeted drug delivery is also described.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Applicant: Imam Abdulrahman Bin Faisal University
    Inventors: B. Rabindran JERMY, Vijaya RAVINAYAGAM
  • Publication number: 20190022008
    Abstract: The present invention provided an apixaban solid composition and a preparation method thereof. The method comprises granulating apixaban by wet granulation, wherein the apixaban has a particle size D90 more than 89 ?m.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 24, 2019
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qibiao HUANG, Xin HUANG, Fangfang HUANG, Jinsong YOU, Feng ZHAO
  • Publication number: 20190022009
    Abstract: A method for obtaining a biopolymer hemostatic powder including adding in an reactor (1) a mixture of an organic acid (b), a combination of alcohols (b) (d) and a bioadhesive to obtain a binder solution and a step of incorporating on a base of the lower part of a fluid bed reactor (2) a polysaccharide (a) driven by an air stream injected at controlled temperature and speed; on which fluid and micro particles of the polysaccharide (a) are sprayed from the top of said fluid bed reactor (2) the binding solution and where the polysaccharide (a) is chitosan, the organic acid (b) is acetic acid, the alcohol combination (c) is alcohol and polyalcohol and the bioadhesive is polyvinyl alcohol.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 24, 2019
    Inventors: Julio Alberto LUNA, Federico Adrian FOOKES, Maria Alejandra CANTEROS
  • Publication number: 20190022010
    Abstract: The invention relates to a process of preparing a salt of an active pharmaceutical ingredient, the process comprising providing a blend of an active pharmaceutical ingredient and a salt forming substance, mixing the blend, optionally in the presence of added water, to react the active pharmaceutical ingredient with the salt forming substance to provide the salt of the active pharmaceutical ingredient; wherein when the active pharmaceutical ingredient is acidic, the salt forming substance is a base and the pKa difference between the acidic active pharmaceutical ingredient and the base is greater than 1, typically greater than 2 or preferably greater than 3; or when the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is greater than 1, typically greater than 2 or preferably greater than 3,
    Type: Application
    Filed: January 16, 2017
    Publication date: January 24, 2019
    Inventors: Mohammed Maniruzzaman, Saumil Kiritkumar Bhatt, Anwar Ali, Arun Jangra
  • Publication number: 20190022011
    Abstract: A dosage form comprising a tablet core and one or more discontinuous coated regions in various configurations on the surface of the dosage form is disclosed. A method for making the dosage form is also disclosed.
    Type: Application
    Filed: July 18, 2017
    Publication date: January 24, 2019
    Inventors: Harry Sowden, Gerard McNally, Der-Yang Lee
  • Publication number: 20190022012
    Abstract: The present invention relates to a method for producing a pharmaceutical delivery system, the use of a surface-reacted calcium carbonate for improving the friability of a pharmaceutical delivery system as well as for improving the flowability of a pharmaceutical delivery system and a pharmaceutical delivery system obtained by the method.
    Type: Application
    Filed: December 16, 2015
    Publication date: January 24, 2019
    Inventors: Jörg Huwyler, Maxim Puchkov, Tanja Stirnimann, Susanna Atria
  • Publication number: 20190022013
    Abstract: A product and process of manufacturing an edible soft-chewable dosage form for the delivery of pharmaceutically active ingredients or nutritional agents orally to an animal or human subject, by forming a granulated soft-chew mass by appropriate mixing and sifting steps, and forming tablets with a compression press. Such soft-chew dosage forms have hardness of less than about two kilopond (2 kp) and friability of less than about one percent (1%) at three-hundred (300) rotations when measured according to the United States Pharmacopeia (USP) test. The process for manufacturing such compressed soft-chew tablets employs compression (tablet) pressing equipment to produce soft-chew tablets of consistent weight and texture.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: First Time US Generics LLC
    Inventors: Manesh A. DIXIT, Vaibhav L. PAWAR, Rushi R. Patel, Mineshkumar D. Patel, Amol SOMWANSHI
  • Publication number: 20190022014
    Abstract: The present invention relates to an enteric coated oral pharmaceutical preparation in the form of a granulate, a pellet or a mini-tablet comprising dimethyl fumarate and having at least two coating layers, i.e. at least one inner enteric coating layer and an outer coating formed by applying a suspension comprising silicon dioxide on the at least one inner enteric coating layer. The invention relates also to the process for obtaining the enteric coated oral preparation of the present invention and to use of the preparation in the treatment of multiple sclerosis.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 24, 2019
    Inventors: Aleksandra Drozd, Przemyslaw Skoczen, Marek Cichocki
  • Publication number: 20190022015
    Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 24, 2019
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Eric FIRST, David Widom
  • Publication number: 20190022016
    Abstract: Controlled release microparticular formulations for the delivery of active agents, especially for treatment of eye diseases or disorders, such as glaucoma, have been developed. These provide release of the active agent, such as a hydrophilic carbonic anhydride inhibitor, for an effective period of time such as a least one month after injection into the eye for treatment of glaucoma.
    Type: Application
    Filed: March 2, 2017
    Publication date: January 24, 2019
    Inventors: Jie Fu, Ian Pitha, Harry Quigley, Justin Hanes
  • Publication number: 20190022017
    Abstract: A microparticle for cell encapsulation is provided, having a core which comprises continuous fibers of decellularized extracellular matrix (ECM) and, optionally, an outer layer. Also provided are methods of encapsulating cells in the microparticle, pharmaceutical compositions comprising the microparticle, and methods of treating disease in animals employing the microparticles of the invention, for example, treating Diabetes.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 24, 2019
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Marcelle MACHLUF, Deborah CHAIMOV
  • Publication number: 20190022018
    Abstract: The present invention provides a method of preparing biomembrane, closed structure with biomembrane characteristics or cellular compartment, comprising the following steps: 1), acquire biological cells from natural tissues or natural biological species; 2), culture the cells obtained in step 1) massively in an appropriate environment; 3), acquire the lysates of cells in step 2), and extracting the biomembrane, closed structure with biomembrane characteristics and cellular compartment through differential centrifugation, density gradient centrifugation or dual-phase extraction individually or a combination of two methods or a combination of three methods thereof. The membrane is a natural biomembrane, closed structure with biomembrane characteristics and cellular compartment, which can be used for package of active ingredients in various fields.
    Type: Application
    Filed: July 19, 2017
    Publication date: January 24, 2019
    Inventors: Ying Gao, Yanming Wang, Jianliang Wei, Minzi Wang, Ye Cheng, Mingzhou Zhang, Liying Ye
  • Publication number: 20190022019
    Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
    Type: Application
    Filed: August 27, 2018
    Publication date: January 24, 2019
    Inventors: Paolo Martini, Vladimir Presnyak
  • Publication number: 20190022020
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • Publication number: 20190022021
    Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.
    Type: Application
    Filed: September 26, 2018
    Publication date: January 24, 2019
    Inventors: Benjamin C. Harrison, James J. Yoo, Anthony Atala
  • Publication number: 20190022022
    Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Applicant: AQUESTIVE THERAPEUTICS, INC.
    Inventors: Alexander Mark Schobel, Stephanie Marie Varjan, Stephen Paul Wargacki
  • Publication number: 20190022023
    Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Applicant: AQUESTIVE THERAPEUTICS, INC.
    Inventors: Alexander Mark Schobel, Stephanie Marie Varjan, Stephen Paul Wargacki
  • Publication number: 20190022024
    Abstract: The present invention relates to an abuse deterrent transdermal patch, particularly transdermal patch for the transdermal administration of oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.
    Type: Application
    Filed: January 18, 2017
    Publication date: January 24, 2019
    Inventor: Kirti VALIA
  • Publication number: 20190022025
    Abstract: The present invention relates to a transdermal patch for the for the transdermal administration of oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.
    Type: Application
    Filed: January 18, 2017
    Publication date: January 24, 2019
    Inventor: Kirti VALIA
  • Publication number: 20190022026
    Abstract: A method and a daily replacement patch for transdermally administering an opioid for analgesic effect. The patch is applied to a subject to deliver the opioid through the skin. The patch may be replaced daily and over an extended period of time.
    Type: Application
    Filed: September 26, 2018
    Publication date: January 24, 2019
    Inventors: Stephen S. Hwang, Robert M. Gale
  • Publication number: 20190022027
    Abstract: The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 24, 2019
    Inventors: Giuseppe Testa, Sina Atashpazgargari, Antonio Adamo, Pierre-Luc Germain, Giuseppe Merla, Giuseppe D'Agostino, Matteo Zanella
  • Publication number: 20190022028
    Abstract: A chemical composition for human consumption includes a cannabinoid composition mixed in an oil-based delivery system. The cannabinoid composition may include cannabidiol (CBD) and the oil-based delivery system may include caprylic acid (C8). In a preferred embodiment, the chemical composition comprises CBD oil and caprylic acid. Another embodiment, directed to a method of producing a chemical composition for human consumption, includes the steps for mixing a cannabinoid composition into an oil-based delivery system.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 24, 2019
    Inventor: Annabelle Manalo
  • Publication number: 20190022029
    Abstract: Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C?C—, (a tolan), —CH?CH— (a stilbene, preferably trans); or —CRa?CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3?, 4, 4?, and/or 5, 5?; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ?1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 24, 2019
    Applicant: BioMendics, LLC
    Inventors: Chun-che Tsai, Karen M. McGuire, James M. Jamison, Jack L. Summers
  • Publication number: 20190022030
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Publication number: 20190022031
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Publication number: 20190022032
    Abstract: A method for killing hematopoietic and/or lymphoid tissue cancer cells is provided. The method includes a step identifying a subject having hematopoietic and/or lymphoid tissue cancer with circulating cells or DNA containing elevated levels of uracils and AP sites. The hematopoietic and/or lymphoid tissue cancer cells are contacted (i.e., treated) with an alkoxyamino compound having formula I: wherein: E is R1, R2, R3, R4, R5 are each independently hydrogen (H), C1-6 alkyl, F, Cl, or Br; and n is 1 to 5.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 24, 2019
    Inventor: Ashok S. BHAGWAT
  • Publication number: 20190022033
    Abstract: The present invention relates to a method of accelerating stem cell engraftement in a patient in need of hematopoietic stem cell transplantation.
    Type: Application
    Filed: March 6, 2017
    Publication date: January 24, 2019
    Inventors: Christoph BUCHER, Peter GERGELY, Andreas KATOPODIS, Philip SMITH
  • Publication number: 20190022034
    Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Inventors: David Devos, Caroline Moreau, Charlotte Laloux, Jean-Christophe Devedjian
  • Publication number: 20190022035
    Abstract: A method of forming a gel implant in tissue can include: providing an injectable composition configured for thermoreversible gel formation at about 37° C.; injecting the injectable composition into the tissue at the rate of about 10-12000 injections per minute; and forming a thermoreversible gel at about 37° C. from the injected injectable composition so as to form the gel implant. The injecting can be at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The injecting can form an implant with area greater than or equal to 5 mm2. The injecting can be at a depth of 10 microns to 5 mm. The injectable composition can include a visualization agent, drug or other agent.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 24, 2019
    Inventor: Chandrashekhar P. Pathak
  • Publication number: 20190022036
    Abstract: A method of ameliorating pain for a duration of at least 3 months due to an intermetatarsal neuroma in a patient, comprising administering by injection into or adjacent to the patient's intermetatarsal space having an intermetatarsal neuroma at least a first dose of capsaicin and a second dose of capsaicin, no sooner than one month after the first dose, to ameliorate pain due to the intermetatarsal neuroma.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 24, 2019
    Inventors: James N. Campbell, Peter D. Hanson, Randall Stevens
  • Publication number: 20190022037
    Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 24, 2019
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, David GRIERSON, Florence MAHUTEAU-BETZER, Pierre ROUX
  • Publication number: 20190022038
    Abstract: Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II): The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 24, 2019
    Inventors: Yi Tsun Richard KAO, Peng GAO, Xuechen LI, Ming LIU
  • Publication number: 20190022039
    Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the present specification, or a salt thereof are useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Applicant: AJINOMOTO CO., INC.
    Inventors: Tomohiro FUJII, Koji OHSUMI, Seiji KITAJIMA, Yoshiro KITAHARA
  • Publication number: 20190022040
    Abstract: Valproate is useful as an antifungal agent. The valproate compositions can be used to treat fungal infections. The valproate compositions can be formulated as topical antifungals.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Wayne State University
    Inventors: Miriam L. Greenberg, Rania M. Deranieh
  • Publication number: 20190022041
    Abstract: A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 24, 2019
    Inventors: RAVIGADEVI Sambanthamurthi, TAN Yew Ai, VERA Vladimirovna Koledova, ROBERT Paul Weinberg, CHO Kyun Rha, ANTHONY J. Sinskey
  • Publication number: 20190022042
    Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 24, 2019
    Inventor: David A. DILL
  • Publication number: 20190022043
    Abstract: Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 24, 2019
    Inventor: Alfred P. Spada
  • Publication number: 20190022044
    Abstract: The present disclosure provides new salts of 5-aminolevulinic acid (5-ALA) and new salts of 5-ALA esters, their preparation, formulation and use as photosensitizing agents in photodynamic therapy, diagnosis and cosmetic cares.
    Type: Application
    Filed: January 24, 2017
    Publication date: January 24, 2019
    Inventors: MING ZHAO, LI-MING ZHOU
  • Publication number: 20190022045
    Abstract: Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Applicants: WASEDA UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yoichi NAKAO, Shigetaka ASANO, Daisuke ARAI, Yukari KASE, Teppei SHIMOMOTO
  • Publication number: 20190022046
    Abstract: The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C8 to C16 fatty acids and/or fatty acid esters.
    Type: Application
    Filed: May 25, 2018
    Publication date: January 24, 2019
    Inventors: Hua Zhu, Judith Louise Flanagan
  • Publication number: 20190022047
    Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.
    Type: Application
    Filed: July 25, 2018
    Publication date: January 24, 2019
    Inventors: Jae Wha KIM, Sei-Ryang OH, Kyung Seop AHN, Ho Bum KANG, Jae Min SHIN, Young Eun KO, Tae Suk LEE, Myung Hwan KIM, Jong Koo KANG, Yong-Hae HAN, Ki-Young SOHN
  • Publication number: 20190022048
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventor: Martin P. MAGUIRE
  • Publication number: 20190022049
    Abstract: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C?O or CH2; Y is NH, O or absent; R is a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T½=12˜24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoid environmental oxidation and increase the environmental stability of drugs containing the compounds.
    Type: Application
    Filed: February 22, 2017
    Publication date: January 24, 2019
    Inventors: Xuemin ZHANG, Xinhua HE, Tao ZHOU, Zhenggang LIU, Tao LI
  • Publication number: 20190022050
    Abstract: Peroxide of the formula wherein R1 is selected from linear and branched alkyl groups with 1-4 carbon atoms, and R2, R3, and R4 are selected from hydrogen and linear and branched alkyl groups with 1-4 carbon atoms, for use as a medicament, in particular for the treatment of acne.
    Type: Application
    Filed: August 25, 2016
    Publication date: January 24, 2019
    Inventors: Ross Christian OPSAHL, Steluta Gina BUTUC
  • Publication number: 20190022051
    Abstract: The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 24, 2019
    Inventor: James E. Vath
  • Publication number: 20190022052
    Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Application
    Filed: January 24, 2017
    Publication date: January 24, 2019
    Inventor: Christopher U. Missling
  • Publication number: 20190022053
    Abstract: The present invention is related to pharmaceutical formulations and methods of treating a subject afflicted with the influenza virus, the method includes administering to the respiratory tract of the patient particles that include more than about 5% to about 50% weight percent (wt %) of a neuraminidase inhibitor. The particles are delivered to the patient's pulmonary system, including the upper airways, central airways and deep lung.
    Type: Application
    Filed: January 8, 2018
    Publication date: January 24, 2019
    Inventors: Kevin L. Ward, Thean Y. Yeoh, Rebecca Martin, Charles D. Blizzard
  • Publication number: 20190022054
    Abstract: The present invention relates to the use of cannabis and cannabinoids, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC) or derivatives thereof in the manufacture of a medicament for the treatment of symptoms associated with antidepressant cessation. Preferably the ratio of the CBD type compounds to the THC type compounds is between about 20:1 and 1:20. More preferably the CBD and THC type compounds or derivatives thereof are in the form of plant extracts.
    Type: Application
    Filed: February 17, 2017
    Publication date: January 24, 2019
    Applicant: Vireo Health LLC
    Inventors: Eric Greenbaum, Kyle Kingsley
  • Publication number: 20190022055
    Abstract: Described herein are compositions comprising one or more United States Pharmacopeial Convention (USP) grade food ingredients mixed together with a cannabinoid. In some embodiments of the compositions and methods described herein, the compositions comprises a mixture which comprises a food item or a meal containing cannabinoid.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventors: Corey A. SIEGEL, Joshua KORZENIK, Michael K. ALLIO, Herbert B. STERN